Zawya - Press Releases: The King Fahd bin Abdulaziz Al Saud Chair for Medical Biotechnology organizes a scientific symposium on genomics and biodiversity

The King Fahd Bin Abdulaziz Al Saud Chair for Medical Biotechnology at the Arabian Gulf University hosted a scientific seminar entitled “Genomics for Biodiversity: Exploring Africa’s Genetic Wealth in the Age of Genomics”, in which Dr. Abdullah Sharaf, Professor at the University of Konstanz in Germany, Bioinformatics Specialist at the SequAna Center for Genetic Sequencing Analysis, and Professor of Genetics at Ain Shams University in Egypt, spoke.

The remote seminar focused on highlighting the importance of biodiversity genomics in revealing the genetic wealth of the African continent in light of the rapid developments in the age of genomics, highlighting the role of modern technologies in reading and sequencing genomes, and building genetic databases that contribute to supporting scientific research and preserving biodiversity.

Dr. Sharaf is a leading researcher in the field of comparative genomics and genome evolution, particularly in single-celled eukaryotes. He also actively participates in the African Biogenomics Project, where he serves as co-chair of the Science, Technology, Monitoring and Evaluation Committee, contributing to capacity-building efforts and the development of genomic data across the African continent.

The seminar was moderated by Dr. Mohammed Belhassen, Assistant Professor and Head of the Department of Molecular Medicine at Arabian Gulf University, as part of the Chair’s efforts to promote international scientific cooperation, attract distinguished research expertise, and support the fields of biotechnology and genomic research. This event is part of a series of scientific seminars organized by the Chair with the aim of disseminating knowledge and promoting academic dialogue in the fields of advanced life sciences.

For her part, Dr. Mai Sater, the General Supervisor of Scientific Chairs at the Arabian Gulf University and Supervisor of the King Fahd bin Abdulaziz Al Saud Chair for Medical Biotechnology, affirmed that the university is committed to supporting pioneering scientific initiatives that contribute to the development of research and innovation in the fields of genomics and biotechnology. She added that the scientific chairs will continue their role in strengthening international partnerships and building research capabilities, stressing that the university has many upcoming plans and projects that will advance knowledge and serve scientific development in the region.

Disclaimer regarding the content of press releases
The content of this press release is provided by a third-party provider. We do not assume any responsibility for, nor do we have any control over, such content. This content is provided on an "as is" and "as available" basis and is not edited in any way. Neither we, nor our affiliates, will be liable for the accuracy, endorsement, or completeness of any opinions, views, information, or materials contained in this content.
This press release is provided for informational purposes only; the content does not constitute legal, investment, or tax advice, nor does it offer any opinion on the suitability, value, or profitability of any particular portfolio or investment strategy. Neither we nor our affiliates will be liable for any errors or inaccuracies in the content, or for any actions you take based on that content. You expressly agree and acknowledge full responsibility for your use of the information contained in this press release.
To the extent permitted by applicable law, Refinitiv, its parent company, subsidiaries, affiliates, relevant shareholders, directors, officers, employees, agents, advertisers, content providers, and licensors (collectively, the 'Refinitiv Parties') shall not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages; This includes, but is not limited to, losses of profits, savings, or revenues, whether due to negligence, tort, contract, or other theories of liability, even if the parties to Refinitiv were advised of the possibility of any such damages or losses occurring or actually anticipated them.